MedTrace Logo

A Study to Assess Current Standard Malaria Treatment Guidelines in the Republic of the Sudan

NCT02592408 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 320

Last updated 2017-02-01

No results posted yet for this study

Summary

This is a randomized controlled trial to assess the efficacy and safety of the national malaria treatment guidelines, asses the efficacy and safety of artesunate and sulphadoxine - pyrimethamine (AS+SP) for treatment in uncomplicated P. falciparum and P. vivax malaria and the hematologic effect of 14 days routine primaquine based radical cure in patients suffering from a P. vivax or mixed infection.

Conditions

Interventions

DRUG

ASP

3 days of artesunate sulfadoxine/pyrimethamine on days 0-2

DRUG

SDPQ

single dose primaquine on day 2

DRUG

14DPQ

14 day primaquine starting on day 2

DRUG

14DPQ on Day 42

14 day primaquine starting on day 42

Sponsors & Collaborators

  • University of Khartoum

    collaborator OTHER

  • Menzies School of Health Research

    lead OTHER

Principal Investigators

  • Muzamil Mahdi, PhD · University of Khartoum

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2016-05-31
Completion
2016-05-31

Countries

  • Sudan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02592408 on ClinicalTrials.gov